NEW YORK (GenomeWeb News) – Genometry announced today that it has signed a multi-year deal with Janssen Pharmaceutica to generate gene-expression profiles from 250,000 compounds in Janssen's small-molecule screening library using its L1000 Expression profiling system.
The L1000 is designed to produce high-dimensional, gene-expression profiles from crude cell lysates in a 384-well plate format. The technology was developed at the Broad Institute, MIT, and the Dana-Farber Cancer Institute, and exclusively licensed by Genometry for pharmaceutical applications.
Genometry said that data generated under the arrangement will be used for primary screening and library characterization, as well as to help Janssen better select drug candidates for clinical development.
Additional terms of the deal were not disclosed.